BRIEF

on Limes Schlosskliniken AG (isin : DE000A0JDBC7)

Limes Schlosskliniken AG Shows Promising Growth

Limes Schlosskliniken AG has reported a promising first half of 2025 with a 29.2% rise in sales, reaching €29.7 million. The addition of new clinics, Abtsee and Bergisches Land, contributed significantly, adding €7.4 million in revenue. The strong performance is highlighted by an increase in billed patient days by 17.5% and a 10% rise in revenue per day.

The company's EBITDA increased by 12% to €7.0 million, although the margin decreased to 23.6%. This decline is primarily due to increased personnel and rent expenses. Both new clinics showed positive results within six months, demonstrating Limes' ability to quickly reach profitability.

Free cash flow saw a substantial rise to €4.8 million, driven by a decrease in capex. These results affirm Limes' asset-light model effectiveness, supporting potential European expansion. With undeterred demand and plans for future openings, the company reiterates a "BUY" recommendation with a target price of €810.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Limes Schlosskliniken AG news